Results of an open-label phase 2 study evaluating PPS safety and tolerability in MPS I
Source: Bratkovic D, et al
March 14, 2023
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Paradigm Biopharmaceuticals. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Paradigm Biopharmaceuticals a question about this update.